Please login to the form below
chemotherapy
This page shows the latest chemotherapy news and features for those working in and with pharma, biotech and healthcare.
London cancer hub launched by Cancer Research UK
I started having chemotherapy at Addenbrookes in Cambridge, but that didn’t work so I had a stem cell transplant.
Latest news
-
Gilead optimistic about Yescarta deal in UK
Both sides are now looking to resolve these two questions. NICE wants to compare Yescarta to patients taking salvage chemotherapy but Gilead wants to make sure a suitable group is selected,
-
MSD wins key EU approval for Keytruda, Alimta combo
Immunotherapy blockbuster Keytruda has received another boost with the European approval of its use in combination with Lilly’s Alimta plus chemotherapy in non-small cell lung cancer (NSCLC). ... Compared to those on Alimta and chemotherapy alone,
-
FDA gives Loxo breakthrough tag for second cancer drug
The BTD covers patients with metastatic RET-fusion-positive non-small cell lung cancer (NSCLC) who have progressed despite earlier therapy with chemotherapy and checkpoint inhibitors, as well as last-line
-
Darzalex powers ahead with frontline myeloma approval in Europe
chemotherapy and autologous stem cell transplant (ASCT), a key front-line treatment strategy.
-
Daily Brief: Jazz Pharma and Ultragenyx approvals, Autonomous AI in retinopathy
Therapy related AML accounts for around 10% of all AMLs, and are caused by a patient's exposure to chemotherapy and/or radiation for a primary malignancy or autoimmune disease. ... Vyxeos is the first chemotherapy to demonstrate an overall survival
More from news
Approximately 6 fully matching, plus 822 partially matching documents found.
Latest Intelligence
-
Cancer immunotherapy: What's on the horizon?
Last year, the FDA approved Merck’s Keytruda (pembrolizumab) as a first-line agent alongside chemotherapy for metastatic NSCLC on data showing the chance of cancer progression was cut in half. ... Opdivo after standard treatment of early-stage lung
-
The threat of antimicrobial resistance
After all, so many of today’s life-saving healthcare advances, from cancer chemotherapy to heart surgery, rely on effective antibiotics being available to prevent infections in patients.
-
Taking a lean and careful approach
Chemotherapy and Pharmacology, which concluded its treatment regimen showed ‘encouraging clinical benefit’.
-
Reactivating drug research programmes
In the case of cancer treatment, such drugs could also help to limit the use of traditional chemotherapy, which can be costly and have undesirable side effects.
-
Deal Watch February 2017
As an ADC IMMU-132 contains SN-38, which is the active metabolite of the chemotherapy agent irinotecan, conjugated to an anti-TROP-2 antibody.
More from intelligence
Approximately 0 fully matching, plus 20 partially matching documents found.
Latest appointments
-
Dr Sotirios Stergiopoulos leaves Shire for Ipsen
affairs strategies and a strong expertise in oncology drug development that includes chemotherapy, immunology drugs and targeted agents across various tumour indications.
-
BMS appoints oncology development head
Dr Namouni first joined Bristol-Myers Squibb in France in 1999 as a life-cycle manager for chemotherapy drug Taxol (paclitaxel) and has since held a number of increasingly senior positions
-
AP Pharma overhauls senior management team
AP Pharma's lead product APF530 for the prevention of chemotherapy-induced nausea and vomiting.
-
AP Pharma appoints Dendreon’s Jesse Hollingsworth to lead sales
AP Pharma appoints Dendreon’ s Jesse Hollingsworth to lead sales. Joins as company prepares to advance APF350 to treat side effects of chemotherapy. ... The appointment comes as AP Pharma prepares to advance its lead product APF350, which is intended
-
Bayer’s former oncology head Robert Rosen joins AP Pharma
Bayer’ s former oncology head Robert Rosen joins AP Pharma. Will lead launch of drug to prevent chemotherapy-induced nausea. ... In this role he will lead efforts at the US-based specialty pharma company to launch APF530 – AP Pharma's lead product
More from appointments
Approximately 0 fully matching, plus 6 partially matching documents found.
Latest from PMHub
-
CASE STUDY: Creation of Global Value Dossiers for a US-based Global Pharmaceutical Company
Febrile Neutropenia (FN) during adjuvant chemotherapy is associated with significant morbidity, mortality risk, and incremental costs. ... The client wanted a vendor to develop content for a Global Value Dossier (GVD) about the burden of febrile
-
Virtual reality—a change for the better in medical education
Virtual reality as a distraction intervention for women receiving chemotherapy. Oncol Nurs Forum. ... 2012; 181:53– 7. Schneider SM, Kisby CK, Flint EP. Effect of virtual reality on time perception in patients receiving chemotherapy.
-
Forecasting in Dynamic Oncology Markets
future. Industry commentators believe immuno-oncology to be the third major breakthrough in cancer treatment, following the early days of chemotherapy and the targeted treatments that followed on from them. ... Only by combining with traditional
-
How pembrolizumab will change the management of advanced lung cancer
Summary/transcript. The Phase III KEYNOTE-024 trial assessed pembrolizumab compared to standard of care (SOC) platinum-based chemotherapies in patients with previously untreated stage IV, programmed cell death ligand 1
-
Products as portfolios: positioning immuno-oncology products
These changes, in turn, are having a fundamental impact on approaches to treatment and standards of care in the same way that surgery, radiotherapy, and chemotherapy have done in the past.
More from PMHub
Approximately 0 fully matching, plus 12 partially matching documents found.
Featured jobs
-
Systematic Review Lead- London
-
Negotiable
- Medical Writers Required - Hertfordshire
-
Competitive
- Senior Strategist/ Planner, Healthcare Marketing, London
-
Excellent package
- Senior Writer, Healthcare Advertising, London
-
Excellent package
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
- Account Manager, Healthcare Advertising
-
£30 - 38, 000 (or -)
-
Senior Medical Writer
-
Salary is DOE
- Senior Medical Writer, MedComms Agency
-
£40 - 55, 000 according to skills and experience benefits
- Account Director, Healthcare Communications Agency
-
£54, 000- £60, 000
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
-
Healthcare PR Senior Account Manager
-
Salary TBC
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
- Account Director or Senior Account Director
-
Salary TBC
-
Account Manager
-
Negotiable
-
Sudler London - Account Director
-
Competitive
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
- Senior Medical Writer, MedComms Agency
-
Salary TBC
-
Associate Scientific Director
-
Salary TBC
- Sudler London - Senior Medical Writer
-
Competitive
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
Subscribe to our email news alerts
- Nurturing the growth mindset: The need for ongoing professional development in strategic medical communications
- Innovate UK supports AI drug discovery project worth £1m
- Nurturing the growth mindset: The need for ongoing professional development in strategic medical communications
- Superhuman editor wins promotion at Porterhouse Medical
- Kymriah rejected in DLBCL - but NICE wants to keep talking about cost effectiveness
- Biotech leaders jump into US free speech debate
PMHub
Complete Medical Communications (CMC)
CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...
Latest intelligence
- PM Society Digital Awards – the power of together
- Our chief executive, Emma Statham, writes about the value of awards and the power of together....
- Seduce anyone in four simple steps
- You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
- What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
- GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....
Quick links
Infographics
